Peptide Name
|
Function
|
Tracer
|
Tissue or cell
|
|
References
|
galantide (M15), galanin-(1-12) -Pro-SP-(5-11) amide
|
antagonist
|
|
rat hypothalamus
|
KD(1) less than 0.1 nM and KD(2) approximately 6 nM
|
Langel U, et al. Int J Pept Protein Res. 1992 ; 39(6) :516-22
|
galanin
|
agonist
|
[125I] Galanin
|
rat pancreatic beta-cell line Rin m 5F
|
KD: 1 nM
|
Kask K, et al. Regul Pept. 1995 , 59(3):341-8
|
galanin-(1-16)
|
agonist
|
[125I] galanin
|
rat forebrain and spinal cord
|
IC50: 3 nM
|
Fisone G, et al. Proc Natl Acad Sci U S A. 1989; 86(23) :9588-91
|
M35 [galanin(1-13)- bradykinin (2-9) amide]
|
antagonist agonist ?
|
[125I] M35
|
rat pancreatic beta-cell line Rin m 5F
|
KD = 0.9 +/- 0.1 nM; Bmax=72 +/- 3 fmol/mg protein
|
Kask K, et al. Regul Pept. 1995, 59(3) :341-8
|
M15 (galantide)
|
antagonist
|
|
|
Hill coefficient:0.4-0.5
|
Ogren SO, et al. Eur J Pharmacol. 1993;242(1):59-64
|
Galnon
|
non-peptide agonist
|
|
spinal cord membranes
|
KD:6+/-0.6 microM
|
Wu WP, et al. Eur J Pharmacol. 2003 ;482(1-3):133-7
|
M242
|
|
|
Bowes cells& Chinese hamster ovary cells
|
at hGalR1<1 nM and at hGalR2<10 nM
|
Saar K, et al. Regul Pept. 2001; 102(1) :15-9
|
M38, [galanin(1-13)- (Ala-Leu)3-Ala amide]
|
antagonist
|
|
|
|
Xu XJ, et al. Br J Pharmacol. 1995 Oct;116(3):2076-80
|
M40, [galanin(1-13) -Pro-Pro-(Ala-Leu)2-Ala amide]
|
antagonist in vivo
|
|
|
|
Xu XJ, et al. Br J Pharmacol. 1995 Oct;116(3):2076-80
|
C7 [galanin (1-13)-spantide] 11
|
antagonist
|
|
|
|
Xu XJ, et al. Br J Pharmacol. 1995 Oct;116(3):2076-80
|
Galanin (Porcine)
|
agonist
|
[125I]galanin (porcine)
|
Bowes melanoma cell line
|
KD = 0.05 +/- 0.01 nM; Bmax = 135 +/- 7 fmol/mg protein
|
Heuillet E, et al. Eur J Pharmacol. 1994 ; 269 (2):139-47
|
Galanin (Human)
|
agonist
|
[125I]galanin (porcine)
|
Bowes melanoma cell line
|
IC50 = 0.35 +/- 0.13 nM
|
Heuillet E, et al. Eur J Pharmacol. 1994 ; 269 (2):139-47
|
Social Network Confirmation